Shots:

• FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients- intolerant to bDMARDs
• FINCH-2 results (N= ≥153): ACR20@12wk (66 vs 57.5 vs 31.1) & ACR20@24wk (69.4 vs 54.9 vs 34.5) whereas- ACR70@12wk (21.8 vs 14.4 vs 6.8)- ACR70@24wk (32.0 vs 20.3 vs 8.1) & DAS28LDA@12 (40.8 vs 37.3 vs 15.5)
• Filgotinib was well tolerated in FINCH-2 trial with no new safety issues and occurrence of serious adverse events (4.1 %- 5.2 % 3.4 %) in patients
• Gilead and Galapagos globally collaborated for filgotinib’s development and commercialization. Several trials are assessing filgotinib- including P-III FINCH 2 trial for RA/other inflammatory diseases- the EQUATOR P-II for PA- the TORTUGA study for AS- the DIVERSITY P-III trial for Crohn’s disease and the P-III SELECTION trial for ulcerative colitis

 Ref: Gilead | Image:Gilead